Gaudet, D., Pall, D., Watts, G., Nicholls, S., Rosenson, R., Modesto, K., San Martin, J., Hellawell, J., & Ballantyne, C. (2024). Plozasiran (ARO-APOC3) for Severe Hypertriglyceridemia.
JAMA CARDIOLOGY,
9(7), 620–630.
https://doi.org/10.1001/jamacardio.2024.0959
Lorusso, D., Xiang, Y., Hasegawa, K., Scambia, G., Leiva, M., Ramos-Elias, P., Acevedo, A., Sukhin, V., Cloven, N., Gomes, A., Mejia, F., Reiss, A., Ayhan, A., Lee, J., Saevets, V., Zagouri, F., Gilbert, L., Sehouli, J., Tharavichitkul, E., … ENGOT-cx11-GOG-3047 KEYN. (2024). Pembrolizumab or placebo with chemoradiotherapy followed by pembrolizumab or placebo for newly diagnosed, high-risk, locally advanced cervical cancer (ENGOT-cx11/ GOG-3047/KEYNOTE-A18): A randomised, double-blind, phase 3 clinical trial.
LANCET,
403(10434), 1341–1350.
https://doi.org/10.1016/S0140-6736(24)00317-9